Merck, an American pharmaceutical company, announced that it had created the first anti-Covid pill in October. The tablet, which is a supplement to the vaccine, would serve as a second line of defense against more serious forms.
This Monday, October 25, the European Medicines Agency launched the Merck American Laboratory Accelerated Examination of the pill to combat Covid-19. This simple remedy is expected to be a key tool in the fight against pandemics. It is also complementary to vaccines.
“The EMA Committee for Medicinal Products for Human Use. (CHMP).The European Medicines Agency A review of the oral antiviral drug Molnupiravir has been initiated. […] Merck developed it […] for the treatment of Covid-19 in adults ”The European regulator, based in Amsterdam, stated that this makes it possible to speed-up the process.
Preliminary results of clinical and laboratory studies “Suggests the drug may decrease the ability of SARS CoV-2 […] Covid-19 does not allow the body to reproduce, so patients are not hospitalized or even killed.EMA.
Molnupiravir, an antiviral drug, works by reducing the virus’s ability to reproduce and thereby slowing the progression of the disease. Merck, a laboratory known as MSD outside the United States, conducted a clinical trial that found that the treatment reduces the chance of death and hospitalization for patients who have received positive tests within days.
Molnupiravir is a drug that could be used to treat severe forms of the disease. If it is approved, it would be a huge breakthrough. The EMA will determine if molnupiravir complies with European standards for safety, efficacy, and quality.